ArticleBioengineering & translational medicine2026
Injectable hyaluronic acid-metformin conjugate gel for sustained intra-articular delivery and prevention of post-traumatic osteoarthritis.
Article in Bioengineering & translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Cross-Linked Versus Linear Hyaluronic Acid for Cartilage Repair in Rat Post-Traumatic Osteoarthritis.Journal of orthopaedic research : official publication of the Orthopaedic Research Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We developed an injectable hyaluronic acid-metformin (HA-Met) conjugate gel for localized intra-articular delivery to mitigate post-traumatic osteoarthritis (PTOA). Conjugation was verified by Fourier-transform infrared spectroscopy, proton nuclear magnetic resonance spectroscopy, and high-performance liquid chromatography. In vitro studies showed an initial 24-h burst attributable to unbound Met, followed by prolonged local retention from the conjugated fraction under physiological incubation without hyaluronidase treatment; by contrast, a simple HA + Met mixture released Met in phosphate-buffered saline (PBS) completely in 3 days. In high dosage hyaluronidase-containing PBS, Met retained in the HA-Met conjugate gel up to 4 days. In vivo, Met remained detectable in mouse knee tissues for up to 7 days after a single intra-articular injection of HA-Met conjugate and accumulated with weekly dosing; in contrast, after Met solution or HA + Met mixture injection around 99% of Met was removed from the knee joint in 1 day, low dosage traces of Met remained in the joint up to 2-3 days. In a destabilization of medial meniscus-induced murine PTOA model, weekly HA-Met conjugate injections attenuated cartilage degeneration and joint pathology versus HA or Met alone, which produced only modest effects; sham joints exhibited no pathological changes. The weekly interval was selected to ensure continuous exposure in mice with rapid metabolism and joint clearance and should be viewed as an accelerated proof-of-concept schedule rather than a clinical regimen. These findings support HA-Met conjugate gel as a translational platform that achieves prolonged intra-articular Met retention and disease-modifying benefit in a small-animal PTOA model.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.